Chemours (NYSE:CC) Stock Price Target Lowered at Truist Financial

Chemours (NYSE:CC) had its price target reduced by equities research analysts at Truist Financial from $20.00 to $18.00 in a report issued on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the specialty chemicals company’s stock. Truist Financial‘s price objective indicates a potential upside of 31.05% from the stock’s previous close.

Other equities analysts have also issued reports about the stock. Barclays started coverage on shares of Chemours in a report on Monday, October 12th. They issued an “equal weight” rating and a $16.00 target price on the stock. UBS Group reduced their target price on shares of Chemours from $18.00 to $16.00 and set a “neutral” rating on the stock in a report on Monday, October 5th. Weiss Ratings cut Chemours from a “sell (d)” rating to a “sell (d-)” rating in a research note on Thursday, August 6th. JPMorgan Chase & Co. reduced their target price on shares of Chemours from $22.00 to $15.00 and set a “neutral” rating on the stock in a report on Thursday, August 13th. Finally, Zacks Research upgraded shares of Chemours from a “strong sell” rating to a “hold” rating in a report on Thursday, September 10th. Three research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $17.55.

Chemours Price Performance

NYSE CC traded up $0.65 during mid-day trading on Wednesday, hitting $13.73. The stock had a trading volume of 1,215,368 shares, compared to its average volume of 2,803,360. Chemours has a twelve month low of $10.44 and a twelve month high of $28.67. The company has a debt-to-equity ratio of 18.98, a current ratio of 1.66 and a quick ratio of 0.88. The firm’s 50 day moving average is $14.12 and its 200 day moving average is $18.25. The stock has a market capitalization of $2.07 billion, a price-to-earnings ratio of -13.46 and a beta of 1.47.

Chemours (NYSE:CC) last issued its earnings results on Monday, November 2nd. The specialty chemicals company reported $0.21 EPS for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.05). The business had revenue of $1.54 billion during the quarter, compared to analyst estimates of $1.53 billion. Chemours had a negative net margin of 2.64% and a positive return on equity of 78.76%. Chemours’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter last year, the company earned $0.40 earnings per share. Equities research analysts forecast that Chemours will post 0.83 earnings per share for the current fiscal year.

Insider Activity at Chemours

In related news, CEO Denise Dignam purchased 3,378 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were acquired at an average cost of $14.95 per share, for a total transaction of $50,501.10. Following the transaction, the chief executive officer owned 339,916 shares of the company’s stock, valued at $5,081,744.20. This trade represents a 1.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Calderon Gerardo Familiar bought 1,935 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The shares were purchased at an average cost of $15.53 per share, with a total value of $30,050.55. Following the purchase, the insider directly owned 58,547 shares of the company’s stock, valued at approximately $909,234.91. This represents a 3.42% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought a total of 8,663 shares of company stock valued at $130,601 over the last three months. 0.85% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Parallel Advisors LLC grew its stake in shares of Chemours by 15.1% during the third quarter. Parallel Advisors LLC now owns 5,926 shares of the specialty chemicals company’s stock worth $80,000 after purchasing an additional 776 shares during the period. Pekin Hardy Strauss Inc. lifted its position in Chemours by 150.6% in the 3rd quarter. Pekin Hardy Strauss Inc. now owns 201,082 shares of the specialty chemicals company’s stock valued at $2,729,000 after acquiring an additional 120,832 shares in the last quarter. Chicago Partners Investment Group LLC acquired a new position in Chemours in the 3rd quarter worth $443,000. VIRGINIA RETIREMENT SYSTEMS ET Al raised its stake in shares of Chemours by 853.8% in the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 99,200 shares of the specialty chemicals company’s stock valued at $1,346,000 after purchasing an additional 88,800 shares during the period. Finally, Sterling Capital Management LLC grew its holdings in shares of Chemours by 839.3% during the third quarter. Sterling Capital Management LLC now owns 5,072 shares of the specialty chemicals company’s stock worth $69,000 after buying an additional 4,532 shares in the last quarter. 76.26% of the stock is currently owned by institutional investors and hedge funds.

Chemours News Roundup

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Chemours launched FaizEon two-phase cooling fluids for AI and high-performance-computing data centers, targeting lower energy and water use as computing heat loads rise. The product could open a new growth opportunity, though its financial contribution is not yet established. Article: Chemours launches FaizEon cooling solutions
• Positive Sentiment: The company forecast fourth-quarter revenue of $1.7 billion–$1.8 billion, above the cited analyst consensus of $1.4 billion. Full-year revenue guidance of $5.9 billion was in line with consensus. Article: Chemours provides earnings guidance
• Neutral Sentiment: Goldman Sachs maintained a Hold rating with a $16 price target, citing strong Q3 results in some respects but weak volumes and a cautious near-term outlook. Article: Goldman Sachs maintains Hold rating
• Negative Sentiment: Q3 adjusted EPS was $0.21, below the $0.26 analyst estimate and down from $0.40 a year earlier. Revenue of $1.54 billion slightly exceeded estimates and rose 3% year over year, but the earnings miss and reported volume weakness weighed on the results. Article: Chemours reports third-quarter results
• Negative Sentiment: Multiple law firms are publicizing a filed securities class action covering investors who bought shares from February 20 to August 4, 2026. The allegations focus on statements about Opteon refrigerant aftermarket demand and distributor inventory; one notice says roughly $65 million in sales may have shifted from 2026 into 2025. The lead-plaintiff deadline is December 7. These reminders add legal and reputational risk, but are not separate new lawsuits. Article: Class-action reminder and allegations

Chemours Company Profile

The Chemours Company (NYSE: CC) is a global chemistry company that develops and manufactures performance chemicals and advanced materials for industrial and consumer applications. The company serves customers in markets including automotive, construction, energy, electronics, healthcare, and general manufacturing.

Chemours operates through businesses focused on Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. Its products include titanium dioxide pigments used to provide whiteness and opacity in coatings, plastics, and paper; refrigerants and related thermal-management solutions; and high-performance fluoropolymers and specialty materials sold under brands such as Teflon™, Viton™, and Nafion™.

Headquartered in Wilmington, Delaware, Chemours serves customers globally through manufacturing facilities, research and development operations, and commercial activities across North America, Latin America, Europe, and Asia-Pacific.